The mean change in hemoglobin in ferumoxytol-treated AUB patients was 2.8 g/dL, compared to no increase (0 g/dL) in AUB patients receiving placebo (p < 0.0001

In a sub-study, mean saliva production in patients receiving Tolenix was restored to a level similar to that of placebo

Results showed that patients receiving Sufentanil NanoTabs realized a significantly greater SPID-48 during the study period than placebo-treated patients (p = 0.001

Avaxia plans to enroll 24 patients in three dose groups, with six patients receiving the study drug and two patients receiving placebo in each dose group, for 28 days

Patients receiving either 1,000-mg or 2,000-mg daily doses of GTx-758 demonstrated significant reductions in their serum-free (unbound) testosterone levels, with related reductions in their levels of serum prostatic specific antigen

Amgen Inc., of Thousand Oaks, Calif., reported results from the Pegfilgrastim and anti-VEGF evaluation study (PAVES), a Phase III trial, which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for first-line treatment of locally advanced or metastatic colorectal cancer...The incidence of grade 3 or 4 febrile neutropenia in patients receiving Neulasta across the first four cycles of chemotherapy was 2.4 percent compared to 5.7 percent in the placebo group

Immunovaccine Inc., of Halifax, Nova Scotia, reported results from a Phase I study showing that all ovarian cancer patients receiving cancer vaccine DPX-Survivac who were evaluable by tetramer staining produced survivin-specific CD8 T cells following one or two vaccinations...All patients receiving DPX-Survivac also demonstrated antigen-specific immune responses, as measured by at least one of the study's three immune monitoring assays

iCo Therapeutics Inc., of Vancouver, British Columbia, said there have been no drug-related serious adverse events among patients receiving repeat doses of iCo-007 at the midpoint of its Phase II iDEAL study in diabetic macular edema

Patients receiving Tolenix, a twice-daily combination of muscarinic antagonist tolterodine and muscarinic agonist pilocarpine, exhibited no safety issues and also demonstrated statistically significant and clinically meaningful improvements in their saliva production and dry mouth side effects, as compared to Detrol

Data showed that 82.3 percent of patients who received oritavancin met the early clinical endpoint of cessation of spread, absence of fever and no rescue antibiotics, compared to 78.9 percent of patients receiving vancomycin

In beta-SPECIFIC 2, 45 percent of patients receiving ACZ885 who were taking corticosteriods at the beginning of the study were able to reduce the dosage substantially, and one-third of patients discontinued steriods

The second Phase III trial resulted in a median two-year progression-free survival rate of 92 percent in patients with diffuse large B-cell lymphoma who received maintenance lenalidomide, compared with 83 percent for patients receiving lenalidomide plus Rituxan (rituximab, Biogen Idec Inc. and Roche AG

All patients receiving sofosbuvir/RBV became HCV RNA negative on treatment and relapse accounted for all virologic failures

Pacira Pharmaceuticals Inc., of Parsippany, N.J., said results from the first IMPROVE study to complete its Phase IV program were published in the Journal of Pain Research and showed a 2.9-day reduction in median length of stay in the hospital (p = 0.004) for patients receiving approved pain drug Exparel in a multimodal regimen...XBiotech Inc., of Austin, Texas, reported an interim analysis from a Phase II study, showing that patients receiving MABp1 to reduce restenosis after percutaneous

Immunomedics Inc., of Morris Plains, N.J., said patients receiving epratuzumab reported clinically meaningful improvements in health-related quality of life (HRQoL) that were sustained over about four years of treatment

In Study 301, 3.8 percent of patients in the PA32540 arm vs. 8.7 percent in the aspirin arm had endoscopically confirmed gastric ulcers (p = 0.02), while, in Study 302, 2.7 percent of patients receiving PA32540 vs. 8.5 percent receiving aspirin had endoscopically confirmed gastric ulcers (p = 0.005

The trials, CARE-MS-I and CARE-MS II, showed that Lemtrada was significantly more effective at reducing annualized relapsed rates than Rebif (high dose subcutaneous interferone beta-1a, Merck Serono) and more patients receiving Lemtrada were relapse-free at two years...Importantly, according to a post hoc analysis, a greater percentage of patients receiving NP001 experienced a halt in disease progression which reached statistical significance when compared to the combination of concurrent and

Initiation of the study followed a successful, dose-escalation Phase I study in which clinical activity was observed in five of seven patients receiving the two highest dose levels

Investigators said 47 percent of patients receiving Simponi 50 mg and 51 percent of patients receiving Simponi 100 mg maintained clinical response through week 54 compared with 31 percent of patients on placebo (p = 0.01 and p < 0.001, respectively